Y-mAbs Therapeutics, Inc.
YMAB · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $204,384 | $199,813 | $351,375 | $586,844 |
| - Cash | $62,293 | $60,310 | $67,234 | $68,122 |
| + Debt | $3,124 | $603 | $820 | $1,075 |
| Enterprise Value | $145,215 | $140,106 | $284,961 | $519,797 |
| Revenue | $19,525 | $20,904 | $26,495 | $18,461 |
| % Growth | -6.6% | -21.1% | 43.5% | – |
| Gross Profit | $16,863 | $17,903 | $18,653 | $16,213 |
| % Margin | 86.4% | 85.6% | 70.4% | 87.8% |
| EBITDA | -$5,604 | -$5,120 | -$5,834 | -$8,447 |
| % Margin | -28.7% | -24.5% | -22% | -45.8% |
| Net Income | -$3,239 | -$5,196 | -$6,790 | -$6,998 |
| % Margin | -16.6% | -24.9% | -25.6% | -37.9% |
| EPS Diluted | -0.072 | -0.12 | -0.15 | -0.16 |
| % Growth | 40.4% | 20% | 6.3% | – |
| Operating Cash Flow | $1,651 | -$6,911 | -$1,870 | -$10,665 |
| Capital Expenditures | $0 | -$127 | $0 | $0 |
| Free Cash Flow | $1,651 | -$7,038 | -$1,870 | -$10,665 |